Detalhe da pesquisa
1.
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Nature
; 594(7863): 418-423, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33953400
2.
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer
; 130(11): 1940-1951, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288862
3.
Development and validation of a machine learning-based predictive model for assessing the 90-day prognostic outcome of patients with spontaneous intracerebral hemorrhage.
J Transl Med
; 22(1): 236, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439097
4.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
5.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534646
6.
Better modulation for risk decision-making after optimized magnetic stimulation.
J Neurosci Res
; 99(3): 858-871, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617027
7.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32737717
8.
The vessel density of the superficial retinal capillary plexus as a new biomarker in cerebral small vessel disease: an optical coherence tomography angiography study.
Neurol Sci
; 42(9): 3615-3624, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33432462
9.
Robust network inference using response logic.
Bioinformatics
; 35(14): i634-i642, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31510692
10.
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.
Bioinformatics
; 35(8): 1350-1357, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30215668
11.
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Invest New Drugs
; 38(2): 419-432, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31020608
12.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31003911
13.
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Br J Cancer
; 121(7): 522-528, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31417188
14.
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol
; 19(4): 510-520, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29477665
15.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449192
16.
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Nature
; 487(7408): 505-9, 2012 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22763448
17.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 17(9): 1248-60, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27480103
18.
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Br J Cancer
; 113(8): 1225-33, 2015 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26379078
19.
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.
J Pathol
; 234(4): 502-13, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25074413
20.
Network quantification of EGFR signaling unveils potential for targeted combination therapy.
Mol Syst Biol
; 9: 673, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23752269